Nucleoside and nucleotide analogs to inhibit the viral RNA polymerase
Total Trials
33
As Lead Sponsor
30
As Collaborator
3
Total Enrollment
5,669
NCT03219957
Study of AT-527 in Healthy and HCV-Infected Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 6, 2017
Completion: Jun 20, 2018
NCT04019717
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
Phase: Phase 2
Start: Jun 20, 2019
Completion: Mar 23, 2020
NCT04396106
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting
Start: May 26, 2020
Completion: Feb 28, 2022
NCT04711187
Study of AT-527 in Healthy Subjects (R07496998)
Start: Nov 2, 2020
Completion: Sep 15, 2021
NCT04709835
Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
Role: Collaborator
Start: Feb 3, 2021
Completion: Oct 13, 2021
NCT04784000
Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527
Start: Mar 1, 2021
Completion: Apr 10, 2021
NCT04722627
Study of AT-752 in Healthy Subjects
Start: Mar 9, 2021
Completion: Nov 14, 2021
NCT04849299
Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)
Start: Apr 18, 2021
Completion: May 10, 2021
NCT04865445
Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)
Start: Apr 22, 2021
Completion: May 15, 2021
NCT04877769
Bronchopulmonary PK of AT-527 (R07496998)
Start: Apr 25, 2021
Completion: Aug 31, 2021
NCT04889040
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
Phase: Phase 3
Start: Apr 28, 2021
Completion: Dec 2, 2021
NCT05059080
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
Phase: N/A
Start: Jun 15, 2021
Completion: Mar 16, 2022
NCT05004415
Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
Start: Jul 28, 2021
Completion: Aug 12, 2021
NCT04309734
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
Phase: Phase 1/2
Start: Oct 31, 2021
Completion: Sep 30, 2022
NCT05137626
Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)
Start: Nov 3, 2021
Completion: Dec 12, 2021
NCT05154123
Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)
Start: Nov 16, 2021
Completion: Dec 23, 2021
NCT05256732
Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal
Start: Feb 22, 2022
Completion: Aug 23, 2022
NCT05366439
Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model
Start: Apr 22, 2022
Completion: Mar 16, 2023
NCT05466240
Study of AT-752 in Patients With Dengue Infection
Start: Apr 29, 2022
Completion: Jan 19, 2023
NCT05618314
Study of AT-527 in Subjects With Normal and Impaired Renal Function
Start: Oct 17, 2022
Completion: Jun 15, 2024
NCT05629962
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Start: Nov 25, 2022
Completion: May 30, 2024
NCT05724693
Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
Start: Jan 30, 2023
Completion: Apr 23, 2024
NCT05731843
Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir
Completion: Mar 15, 2023
NCT05905484
Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects
Start: Apr 25, 2023
Completion: May 31, 2023
NCT05905497
The Study of Bemnifosbuvir in Healthy Japanese Subjects
Start: Apr 26, 2023
Completion: May 19, 2023
NCT05904470
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Start: May 30, 2023
Completion: Jan 28, 2025
NCT06204679
Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
Start: Dec 14, 2023
Completion: Aug 25, 2024
NCT06356194
Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
Start: Apr 15, 2024
NCT06868264
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Start: Apr 7, 2025
Completion: Dec 31, 2026
NCT06921941
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin
Start: Apr 8, 2025
Completion: Jul 2, 2025
NCT06911320
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Start: Apr 9, 2025
Completion: Nov 30, 2025
NCT07007806
Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir
Start: May 9, 2025
Completion: Jun 28, 2025
NCT07037277
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Start: Jun 2, 2025
Completion: Mar 31, 2027
Loading map...